Greg Lucier has become CEO of NuVasive, a medical device company focusing on spine surgery, after serving as the firm's interim CEO since April. He has been a member of NuVasive's board of directors since late 2013 and will continue as the board's chairman.
Until early 2014, Lucier was chairman and CEO of Life Technologies, which was acquired by Thermo Fisher Scientific last year. Previously, he was a corporate officer of General Electric and an executive at GE Medical Systems. Lucier holds a bachelor's degree in engineering from Pennsylvania State University and an MBA from Harvard Business School.
Former Vemillion President and CEO Gail Page has joined NX Prenatal's board as executive chairperson to help guide the molecular diagnostic firm's commercial development of blood-based tests to support improved pregnancy outcomes. Page was president, CEO, and a director at Vermillion from 2006 to 2012. Prior to that, she was on the executive management team at Laboratory Corporation of America and at Luminex. In 2013, she founded Vineyard Investment Advisors.
Patrick Hall, Robert Cook
Castle Biosciences has appointed Patrick Hall as executive director of medical affairs, and promoted Robert Cook to executive director of research and development. Both are newly created positions.
Hall, who will oversee Castle Bio's medical affairs strategies and programs, has 27 years of experience in the industry, including 11 years at Genomic Health, most recently as director of genomic science liaisons. Prior to that, he was medical science liaison at Genentech.
Cook's was previously senior scientist at Castle Bio, which he joined in 2011. He has a Ph.D. from Northwestern University in biochemistry, molecular and cellular biology and did a post-doctoral fellowship at Baylor College of Medicine. Prior to his doctoral degree, he was at Gen-Probe, now part of Hologic.
Donald "Skip" Trump
Donald "Skip" Trump has been named CEO and executive director of the Inova Dwight and Martha Schar Cancer Institute.
Prior to coming to Inova, Trump was CEO and president of Roswell Park Cancer Institute in Buffalo, New York from 2007 to 2014.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.